Discover 243 paid clinical trials in Syracuse, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Syracuse is the medical research centre of central New York, and most of its trial activity runs through one institution: SUNY Upstate Medical University, the region's only academic medical centre and the largest employer in central New York. Cancer research leads the list, with ovarian cancer, lung cancer, and lymphoma studies recruiting through both cooperative groups such as the Alliance for Clinical Trials in Oncology and the National Cancer Institute and through industry sponsors, and migraine and Crohn's disease studies appear alongside them.
Filter
2
Filter results
Results: 243
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Kinematic and Kinetic Effects of Orthotic Devices for Subjects With Stage II Posterior Tibial Tendon Dysfunction
for
Posterior Tibial Tendon Dysfunction
Location: Syracuse NY
Sponsor: State University of New York - Upstate Medical University
Sex: All
Age: 40+
Code: NCT01749657
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Syracuse NY, Verona NY, East Stroudsburg PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06589804
Phase3, Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer